# HIGHLIGHTS

#### **FINANCIAL HIGHLIGHTS**

Significant improvement in cash performance and reduced net debt

Revenue £71.1m ↓**1.9%** 



Underlying\* Basic EPS 12.0p 12.6%



## **£13.1m 11.3%** (+1.7% adjusted)

**Underlying\*\* EBITDA** 







#### STRATEGIC AND OPERATIONAL HIGHLIGHTS

- Strengthened capability in strategically important areas of business development and marketing
- Significant progress towards goal of generating 80% of revenue from top 20 products in pursuit of a more profitable portfolio
- Newly introduced Companion Animal products contributing to sales with £1.5m generated in the year. Four 2019 product launches expected to show sales benefit in 2020
- Internal pipeline progressing with completion of clinical studies and regulatory submission post year end for Enflicoxib E6087 for treatment of pain in dogs
- Partnering efforts yield new distribution deals that strengthen treatment options in growth segments of Companion Animals and Equine

\* A reconciliation of underlying to reported results can be found on page 20

\*\* A reconciliation of underlying to reported results may be found on page 18

#### Strategic Report

#### **Our Business** Highlights 01 02 Chairman's Statement Why Animalcare? 03 Our Products 04 Our Group at a Glance 04 Our Marketplace 06 Our Business Model 08 Our Stakeholders and s172 Statement 10

#### **Our Performance**

Delivering Our Strategy	12
Our Key Performance Indicators	14
Chief Executive Officer's Review	16
Chief Financial Officer's Review	18
Our Principal Risks	24

#### Our Governance

Board of Directors	28
Corporate Governance Statement	32
Corporate Governance Report	34
Audit and Risk Committee Report	38
Remuneration and Nomination Committee Report	41
Directors' Remuneration Report	42
Directors' Report	46
Statement of Directors' Responsibilities	49

### Our Financials

Independent Auditor's Report	50
Consolidated Income Statement	56
Consolidated Statement of Comprehensive Income	57
Consolidated Statement of Financial Position	58
Consolidated Statement of Changes in Equity	59
Consolidated Cash Flow Statements	60
Notes to the Consolidated Financial Statements	61
Company Statement of Financial Position	97
Company Statements of Changes in Shareholders' Equity	98
Company Cash Flow Statement	99
Notes to Financial Statements	100
Advisers	IBC